R-HDAC
R-HDAC, or R-HD-AraC ituximab plus 'igh 'ose ra- is a chemotherapy regimen that is used, alternating with R-Maxi-CHOP, as part of so-called "Nordic protocol" of treating mantle cell lymphoma. It consists of monoclonal antibody rituximab and high-dose antimetabolite cytarabine.
High-dose Ara-C without rituximab also has several other uses in oncohematology. For example, HDAC, alone or alternating with HD-MTX, is often used for primary CNS lymphoma and for treating CNS involvement in any lymphomas, and also for so-called "CNS prophylaxis". HDAC is also used as a consolidation regimen in acute myeloid leukemia after initial 7+3 induction. HDAC also can be used as the primary induction therapy in AML, with higher than in 7+3 success rate, but it is more toxic and causes more treatment-related complications and treatment-related mortality than 7+3 when used as primary induction therapy.Dosing regimen
| Drug | Dose | Mode | Days |
| 'ituximab | 375 mg/m2 | IV infusion | Day 1 |
| 'igh 'ose 'ra-ytarabine | 3000 mg/m2 | IV infusion | Days 1 and 2 |
